Ripertamab

DB16314InvestigationalProtein Based Therapies

Ripertamab is under investigation in clinical trial NCT02772822 (A Study Comparing the Efficiency and Safety of S-chop(cyclophosphamide, Hydroxydaunomycin, Oncovin, and Prednisone) Versus R-CHOP in Untreated Cd20(cluster of Differentiation Antigen 20)-positive...

Mechanism: Pharmacologically active on B-lymphocyte antigen CD20
Curator reviewed
Also known as: Immunoglobulin g1-kappa, anti-(homo sapiens ms4a1 (membrane-spanning 4-domains subfamily a member 1, cd20)), chimeric monoclonal antibody · Immunoglobulin igg1, anti-(human cd20 antigen) (human-mus musculus monoclonal disulfide sct400 .gamma.1-chain), disulfide with human-mus musculus monoclonal sct400 .kappa.-chain, dimer
Code names: SCT-400

Resolves to

Compound

UNIIURS0374MIVCAS2249927-04-4

Targets

P11836MS4A1

What you can answer from here — as of July 08, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

9Clinical trialsPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with Ripertamab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account